Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 7 of 7 results for tadalafil

  1. Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)

    NICE is unable to recommend the use in the NHS of tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia. This is because Lilly did not provide an evidence submission

    Technology appraisal guidance
    Published
    23 January 2013

    Sections for TA273

  2. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  25 February 2026

    Technology appraisal guidance
    In development

  4. Erectile dysfunction: Alprostadil cream (ESNM50)

    Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 December 2014

  5. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    12 August 2014

  6. Macitentant–tadalafil for treating pulmonary arterial hypertension [TSID10517]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)

    This evidence summary has been updated and replaced by NICE guideline CG97.

    Evidence summary
    Published
    23 May 2013